|Mr. Leonard L. Mazur||Exec. Chairman & Sec.||410k||N/A||1945|
|Mr. Myron Z. Holubiak||Pres, CEO & Director||735k||N/A||1947|
|Mr. Jaime Bartushak||CFO & Chief Accounting Officer||440k||N/A||1968|
|Dr. Myron S. Czuczman M.D.||Exec. VP & Chief Medical Officer||436.42k||N/A||1959|
|Mr. Gary F. Talarico||Exec. VP of Operations||N/A||N/A||1955|
|Ilanit Allen||VP of Corp. Communications & Investor Relations||N/A||N/A||N/A|
|Mr. Dhananjay G. Wadekar||Sr. VP of Bus. Strategy||N/A||N/A||1954|
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products targeting medical needs with a focus on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing four proprietary products, including Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Citius Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.